Skip to content
AnalystLens

IQVIA Holdings 8-K Report, Financial Results (Oct 27, 2026)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed October 27, 2026
Period End
October 27, 2026
Security
IQV
In the record · 2016–202610-K1110-Q338-K130

IQV filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 130 current reports (8-K) between 2016 and 2026.

  1. Leadership change8-K · Jul ’17Jul ’17
  2. Material agreement8-K · Dec ’19Dec ’19
  3. Leadership change8-K · Jan ’22Jan ’22
  4. Material agreement8-K · Dec ’25Dec ’25

01—Abstract

Summary

Summary of the 8-K filed October 27, 2026. Cited figures are marked; the original filing is the authoritative source.

IQVIA Holdings Inc. reported record third-quarter 2026 results, with revenue of $4,428 milliona, up 8.0% year-over-year (8.6% at constant currency).

GAAP net income was $350 millionb and GAAP diluted EPS was $2.10. Adjusted EBITDA rose to $1,032 million, up 8.7%, and Adjusted Diluted EPS was $3.34, up 11.3%. R&D Solutions net new bookings reached $3.2 billion, up 15%, with a book-to-bill ratio of 1.2x.

Management cited favorable demand indicators and said its organic growth acceleration was double the prior rate for Commercial Solutions and nearly triple for clinical. The company also adjusted R&DS contracted backlog following a review of inactive trials. The backlog adjustment was approximately $2.1 billionc and, per the filing, had no impact on historical financial results, 2026 guidance, book-to-bill, or next-twelve-month revenue from backlog.

R&DS contracted backlog stood at $32.6 billiond as of September 30, 2026, with approximately $9.4 billion expected to convert to revenue in the next twelve months, representing 10% year-over-year growth. IQVIA raised its full-year 2026 guidance for revenue to $17,350 million–$17,500 million, Adjusted EBITDA to $4,025 million–$4,055 million, and Adjusted Diluted EPS to $12.90–$13.00. Net debt was $13,818 million and the Net Leverage Ratio was 3.45x trailing twelve-month Adjusted EBITDA.

Free cash flow for the quarter was $667 million, equal to 120% of Adjusted Net Income. The company will hold an Investor Day on December 1, 2026.

02—Key points

Key Highlights

  1. Q3 2026 revenue of $4,428 million, up 8.0% year-over-year (8.6% at constant currency); Commercial Solutions $1,789 million (up 6.9%) and R&D Solutions $2,639 million (up 8.7%).
  2. GAAP diluted EPS of $2.10 and Adjusted Diluted EPS of $3.34, up 11.3% year-over-year; Adjusted EBITDA of $1,032 million, up 8.7%.
  3. R&DS net new bookings of $3.2 billion, up 15% year-over-year, with a 1.2x book-to-bill ratio; last-twelve-month net new bookings of $11.7 billion, up 14%.
  4. Backlog adjustment of approximately $2.1 billion from a review of inactive trials; R&DS contracted backlog of $32.6 billion, with about $9.4 billion expected to convert to revenue in the next twelve months, up 10%.
  5. Full-year 2026 guidance raised for revenue ($17,350–$17,500 million), Adjusted EBITDA ($4,025–$4,055 million) and Adjusted Diluted EPS ($12.90–$13.00); guidance includes 250 basis points of acquisition contribution and about 20 basis points of foreign exchange tailwind.
  6. Operating cash flow of $825 million and free cash flow of $667 million in Q3, equal to 120% of Adjusted Net Income; net debt of $13,818 million and Net Leverage Ratio of 3.45x.
  7. Investor Day scheduled for December 1, 2026, with management providing a business update.

03—Questions

Frequently Asked Questions

  1. How large is the backlog adjustment, and does it affect reported results or guidance?

    The company adjusted R&DS backlog by approximately $2.1 billion after reviewing inactive trials. The filing states the adjustment has no impact on historical financial results, 2026 guidance, book-to-bill, or next-twelve-month revenue from backlog estimates.

  2. What drove the raised 2026 guidance?

    IQVIA raised full-year 2026 guidance for revenue, Adjusted EBITDA and Adjusted Diluted EPS. Revenue guidance now anticipates 250 basis points of contribution from acquisitions, including deals expected to close by year-end, and about 20 basis points of foreign exchange tailwind. Guidance assumes exchange rates as of October 26, 2026.

  3. How strong is the company's cash generation and balance sheet?

    Q3 operating cash flow was $825 million and free cash flow was $667 million, equal to 120% of Adjusted Net Income. As of September 30, 2026, cash and cash equivalents were $2,249 million, debt was $16,067 million, net debt was $13,818 million, and the Net Leverage Ratio was 3.45x trailing twelve-month Adjusted EBITDA.

  4. What demand signals did management highlight?

    Management cited favorable EBP funding, RFP flow, clinical trial starts, FDA approvals, outsourcing trends and pipeline growth across clinical and commercial. It also pointed to the strongest clinical quarterly bookings since 2022 and over 400 AI agents deployed to date.

  5. What should investors watch next?

    The Investor Day on December 1, 2026 will provide an update on the business, with presentations from senior executives starting at 9:00 a.m. ET. The filing also notes the company may not achieve the expected benefits of its reorganized two-segment structure.

04—Continue

← View all 8-K filings